P
PPBT
vs
S&P 500
S&P 500
Over the past 12 months, PPBT has underperformed S&P 500, delivering a return of -85% compared to the S&P 500's +17% growth.
Stocks Performance
PPBT vs S&P 500
Performance Gap
PPBT vs S&P 500
Performance By Year
PPBT vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Purple Biotech Ltd
Glance View
Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The firm is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.